- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 21.04. | BigHat & Lilly Partner on AI Antibody Discovery | ||
| 21.04. | FDA Approves Dupixent in the U.S. for Chronic Spontaneous Urticaria | ||
| 21.04. | Thermo Fisher Scientific Opens Advanced Therapies Collaboration Center | ||
| 21.04. | Rigaku and Spera Pharma Partner to Accelerate Pharmaceutical Development | ||
| 21.04. | Dipharma Earns Bronze EcoVadis Sustainability Rating | ||
| 17.04. | Neurizon Adds Strategic Regulatory and Scientific Leadership | ||
| 17.04. | Ziihera Now Available for HER2+ Biliary Cancer | ||
| 17.04. | Sanofi Licenses AI-Discovered Biologics from Earendil Labs | ||
| 16.04. | Capricorn Scientific Partners with florabio | ||
| 16.04. | Precision Medicine Group Appoints Chief Information and Technology Officer | ||
| 15.04. | BMS Heart Drug Camzyos Disappoints in Phase 3 Study | ||
| 15.04. | Parexel Names Chief Medical Officer | ||
| 15.04. | Cold Chain Technologies Launches CCT Tower Elite | ||
| 15.04. | Cyprumed Enters License and Option Agreement with MSD | ||
| 15.04. | Introducing Meribel Pharma Solutions | ||
| 15.04. | Celltrion's YUFLYMA Approved as Interchangeable Biosimilar to Humira | ||
| 15.04. | Boehringer Ingelheim, Cue Biopharma Partner to Commercialize Therapy for Immune Diseases | ||
| 15.04. | Galapagos CFO and COO Thad Huston Departs August 1 | ||
| 14.04. | Thermo Fisher Scientific Introduces 5L DynaDrive Single-Use Bioreactor | ||
| 14.04. | Lifecore Biomedical Taps Thomas Salus as Chief Legal & Administration Officer | ||
| 14.04. | Lonza Joins Center for Continuous Manufacturing and Advanced Crystallization | ||
| 14.04. | Intas Pharmaceuticals Acquires UDENYCA Business from Coherus BioSciences | ||
| 11.04. | Arcutis Names New Chief Financial Officer | ||
| 11.04. | Novartis to Invest $24B in U.S.-Based Infrastructure | ||
| 11.04. | FDA Approves argenx's VYVGART Hytrulo Prefilled Syringe for Self-Injection |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .